 |
 |
 |
||||
|---|---|---|---|---|---|---|
| Indication | High cholesterol (hyperlipidemia) | Moderate to Moderately severe pain (e.g. osteoarthritis) | Severe acne | |||
| Delivery technology | Oral Lidose® technology | Oral controlled release beads | Oral Lidose® technology | |||
| Benefit | Enhanced absorption under high fat vs. low fat fed conditions | Once-daily dosing (vs. up to six times daily for immediate release) | More consistent absorption under variable dietary conditions | |||
| Stage of development/ commercialization |
US commercial launch in 2007 Marketed by Kown Pharmaceuticals America |
Approved by U.S. FDA in May 2010 US marketing partnership with Vertical Pharmaceuticals Inc; targeting Q3 2011 launch Canadian marketing partnership with Medical Futures Inc; targeting Q1 2012 launch |
Approvable letter from US FDA Phase III safety study completed US |
Cipher Pharmaceuticals is improving drugs for better results. We are a specialty pharmaceutical company that develops improved formulations of known molecules using drug delivery technologies. Currently, we have two FDA-approved products and one late-stage product in our pipeline.